secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2022-10-13T23:59:59+00:00
Accession:  0001493152-22-028331
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo Pharmaceuticals adopts amended bylaws to comply with universal proxy rules
--------------------------------------------------------------------------------

- Board of Directors adopted Amended and Restated Bylaws on October 11, 2022.
- Updated advance notice procedures for stockholder proposals to require additional information.
- Added classified Board provision consistent with existing certificate of incorporation.
- Implemented supermajority stockholder vote requirement for any future bylaw amendments.
- Removed President's authority to call special meetings of stockholders or the Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315222028331/0001493152-22-028331-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315222028331/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-028331

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer